No votes yet

Open Access Article

Lenalidomide: A New Agent for Patients With Relapsed or Refractory Multiple Myeloma

Joseph D. Tariman
CJON 2007, 11(4), 569-574 DOI: 10.1188/07.CJON.569-574

Lenalidomide is a potent, novel thalidomide analog that has demonstrated promising clinical activity in patients with relapsed or refractory multiple myeloma (MM). It is a lead immunomodulatory drug currently approved by the U.S. Food and Drug Administration. Neutropenia, thrombocytopenia, and thromboembolic events are common adverse effects associated with lenalidomide therapy in patients with MM. Careful monitoring of those known serious adverse effects is essential to prevent life-threatening complications. This article discusses lenalidomide's mechanisms of action, clinical trial results, and the management of common adverse effects in patients with MM.